Improving treatment outcomes for patients with HER2‑positive breast cancer using neoadjuvant double HER2 blockade

Improving treatment outcomes for patients with HER2‑positive breast cancer using neoadjuvant double HER2 blockade

Background. Dual anti-HER2-targeted therapy in breast cancer (BC) significantly increased the rate of pathological complete response (pCR) compared to single blockade when added to chemotherapy. However, limited data exist on the long-term impact on survival of the additional increase in pCR.Aim. To...

Full description

Saved in:
Bibliographic Details
Main Authors: V. F. Semiglazov, N. B. Bekkeldieva, P. V. Krivorotko, A. V. Komyakhov, R. M. Paltuev, A. I. Tseluyko, L. P. Gigolaeva, T. T. Tabagua, E. K. Zhiltsova, V. S. Apollonova, G. A. Dashyan, A. G. Kudaybergenova, V. G. Ivanov, A. A. Bozhok, D. G. Ulrikh, A. O. Gorina, T. Yu. Semiglazova
Format: Article
Language:Russian
Published: ABV-press 2024-11-01
Series:Опухоли женской репродуктивной системы
Subjects:
her2-positive breast cancer
stage ii–iii
neoadjuvant double her2 blockade
trastuzumab + pertuzumab
lapatinib + trastuzumab
Online Access:https://ojrs.abvpress.ru/ojrs/article/view/1272
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://ojrs.abvpress.ru/ojrs/article/view/1272

Similar Items